ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

BLRX BioLineRx Ltd

0.6679
0.00 (0.00%)
Pre Market
Last Updated: 12:00:05
Delayed by 15 minutes
Name Symbol Market Type
BioLineRx Ltd NASDAQ:BLRX NASDAQ Depository Receipt
  Price Change % Change Price Bid Price Offer Price High Price Low Price Open Price Traded Last Trade
  0.00 0.00% 0.6679 0.6533 0.69 51 12:00:05

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

17/04/2023 4:09pm

Edgar (US Regulatory)




SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
 
For the month of April 2023
 
Commission file number: 001-35223
 
BioLineRx Ltd.
(Translation of registrant’s name into English)
 
2 HaMa’ayan Street
Modi’in 7177871, Israel
(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
 
Form 20-F        Form 40-F 



On April 17, 2023, the registrant issued the press release which is filed as Exhibit 1 to this Report on Form 6-K.
 


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
BioLineRx Ltd.
 
 
 
 
 
 
By:
/s/ Philip A. Serlin
 
 
 
Philip A. Serlin
 
 
 
Chief Executive Officer
 

Dated: April 17, 2023
 
 

1 Year BioLineRx Chart

1 Year BioLineRx Chart

1 Month BioLineRx Chart

1 Month BioLineRx Chart

Your Recent History

Delayed Upgrade Clock